Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Market Cap	283.92B
Revenue (ttm)	155.49B
Net Income (ttm)	19.68B
Shares Out	70.73M
EPS (ttm)	270.21
PE Ratio	14.86
Forward PE	15.31
Dividend	90.00 (2.24%)
Ex-Dividend Date	Feb 26, 2026

Volume	232,200
Average Volume	225,785
Open	4,011.00
Previous Close	4,011.00
Day's Range	3,991.00 - 4,030.00
52-Week Range	3,783.00 - 4,735.00
Beta	0.42
RSI	39.61
Earnings Date	Jan 8, 2026

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.